← Back
AgomAb Therapeutics
AGMB · listed on Nasdaq · worth $413.68 million
$8.40
−1.98% today
One insider bought $88.8K of AgomAb Therapeutics stock in the last two weeks. The buyer was David R. Epstein.
Green dot = an insider boughtA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
17.4M shares
35% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, three insiders bought AgomAb Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Executive Officer
Tim Jasper Knotnerus
Bought $50.9K on Oct 5 — 6,000 shares at $8.48, 36% of what they now own.
No earlier purchases to measure
Director
David R. Epstein
Bought $44.5K on Oct 21 — 5,000 shares at $8.90, 20% of what they now own.
No earlier purchases to measure
Chief Financial Officer
Pierre Thadee Victor Kemula
Bought $42.9K on Oct 6 — 5,000 shares at $8.57, 63% of what they now own.
No earlier purchases to measure
All reports
Every insider trade and SEC report we hold for AgomAb Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
5 more with Pro →Analysts, earnings and news
Analysts' price target
$37.67 average
6 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.